Millendo Therapeutics (NASDAQ:MLND) Earns Outperform Rating from Analysts at CIBC

CIBC initiated coverage on shares of Millendo Therapeutics (NASDAQ:MLND) in a report published on Tuesday, FirstToMarketsRatingsTable reports. The brokerage issued an outperform rating and a $26.00 price target on the stock.

A number of other research firms also recently commented on MLND. ValuEngine downgraded shares of Welbilt from a hold rating to a sell rating in a research report on Wednesday, June 12th. Citigroup set a $12.00 target price on shares of Controladora Vuela Co Avcn SA CV and gave the stock a buy rating in a research report on Monday. Oppenheimer started coverage on shares of Neurocrine Biosciences in a research report on Tuesday. They issued an outperform rating and a $100.00 target price for the company. Finally, Zacks Investment Research raised shares of Golub Capital BDC from a hold rating to a buy rating and set a $20.00 target price for the company in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $24.38.

Shares of MLND traded up $0.05 on Tuesday, hitting $10.70. 4,660 shares of the stock traded hands, compared to its average volume of 106,299. The stock has a market cap of $141.89 million, a P/E ratio of -0.61 and a beta of 2.61. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.83 and a quick ratio of 7.83. The firm has a 50 day simple moving average of $12.68. Millendo Therapeutics has a one year low of $6.77 and a one year high of $17.34.

Millendo Therapeutics (NASDAQ:MLND) last announced its quarterly earnings results on Wednesday, May 15th. The company reported ($0.78) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.08). On average, equities research analysts forecast that Millendo Therapeutics will post -3.27 earnings per share for the current year.

Hedge funds have recently modified their holdings of the company. Geode Capital Management LLC bought a new stake in shares of Millendo Therapeutics during the 4th quarter valued at $113,000. Private Advisors LLC grew its position in shares of Millendo Therapeutics by 9.1% during the 1st quarter. Private Advisors LLC now owns 15,263 shares of the company’s stock valued at $229,000 after acquiring an additional 1,279 shares during the period. Tibra Equities Europe Ltd bought a new stake in shares of Millendo Therapeutics during the 1st quarter valued at $303,000. BlackRock Inc. bought a new stake in shares of Millendo Therapeutics during the 4th quarter valued at $203,000. Finally, Worth Venture Partners LLC bought a new stake in shares of Millendo Therapeutics during the 4th quarter valued at $206,000. 44.07% of the stock is owned by hedge funds and other institutional investors.

About Millendo Therapeutics

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Further Reading: What are no-load funds?

Analyst Recommendations for Millendo Therapeutics (NASDAQ:MLND)

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.